-
Je něco špatně v tomto záznamu ?
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019
C. Garbe, T. Amaral, K. Peris, A. Hauschild, P. Arenberger, L. Bastholt, V. Bataille, V. Del Marmol, B. Dréno, MC. Fargnoli, JJ. Grob, C. Höller, R. Kaufmann, A. Lallas, C. Lebbé, J. Malvehy, M. Middleton, D. Moreno-Ramirez, G. Pellacani, P....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
- MeSH
- diagnostické zobrazování normy MeSH
- Evropská unie MeSH
- kombinovaná terapie MeSH
- konsensus MeSH
- lidé MeSH
- melanom klasifikace diagnóza terapie MeSH
- mezioborová komunikace * MeSH
- směrnice pro lékařskou praxi jako téma normy MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
A unique collaboration of multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with 1- to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumour thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("Tumor Board"). Adjuvant therapies in stage III/IV patients are primarily anti-PD-1, independent of mutational status, or dabrafenib plus trametinib for BRAF-mutant patients. In distant metastasis, either resected or not, systemic treatment is indicated. For first-line treatment, particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In particular scenarios for patients with stage IV melanoma and a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harbouring a BRAF-V600 E/K mutation, this therapy shall be offered in second-line. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
1st Department of Dermatology Aristotle University Thessaloniki Greece
Center for Dermatooncology Department of Dermatology Eberhard Karls University Tuebingen Germany
Department of Dermatology Erasme Hospital Université Libre de Bruxelles Brussels Belgium
Department of Dermatology Medical University of Vienna Austria
Department of Dermatology University Hospital Schleswig Holstein Campus Kiel Kiel Germany
Department of Dermatology University of L'Aquila Italy
Department of Dermatology Venerology and Allergology Frankfurt University Hospital Frankfurt Germany
Department of Oncology Odense University Hospital Denmark
Dermatology Clinic Maggiore Hospital University of Trieste Trieste Italy
Dermatology Department CHU Nantes CIC 1413 CRCINA University Nantes Nantes France
Dermatology Unit University of Modena and Reggio Emilia Modena Italy
Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy
Institute of Dermatology Università Cattolica Rome Italy
Medical and Surgical Dermatology Service Hospital Universitario Virgen Macarena Sevilla Spain
Melanoma Unit Department of Dermatology Hospital Clinic IDIBAPS Barcelona Spain
NIHR Biomedical Research Centre University of Oxford UK
Portuguese Air Force Health Care Direction Lisbon Portugal
Princess Máxima Center 3584 CS Utrecht the Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025227
- 003
- CZ-PrNML
- 005
- 20201222153744.0
- 007
- ta
- 008
- 201125s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2019.11.015 $2 doi
- 035 __
- $a (PubMed)31866016
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Garbe, Claus $u Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. Electronic address: claus.garbe@med.uni-tuebingen.de.
- 245 10
- $a European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019 / $c C. Garbe, T. Amaral, K. Peris, A. Hauschild, P. Arenberger, L. Bastholt, V. Bataille, V. Del Marmol, B. Dréno, MC. Fargnoli, JJ. Grob, C. Höller, R. Kaufmann, A. Lallas, C. Lebbé, J. Malvehy, M. Middleton, D. Moreno-Ramirez, G. Pellacani, P. Saiag, AJ. Stratigos, R. Vieira, I. Zalaudek, AMM. Eggermont, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC),
- 520 9_
- $a A unique collaboration of multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with 1- to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumour thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("Tumor Board"). Adjuvant therapies in stage III/IV patients are primarily anti-PD-1, independent of mutational status, or dabrafenib plus trametinib for BRAF-mutant patients. In distant metastasis, either resected or not, systemic treatment is indicated. For first-line treatment, particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In particular scenarios for patients with stage IV melanoma and a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harbouring a BRAF-V600 E/K mutation, this therapy shall be offered in second-line. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a diagnostické zobrazování $x normy $7 D003952
- 650 _2
- $a Evropská unie $7 D005062
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mezioborová komunikace $7 D033183
- 650 _2
- $a melanom $x klasifikace $x diagnóza $x terapie $7 D008545
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $x normy $7 D017410
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Amaral, Teresa $u Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany; Portuguese Air Force Health Care Direction, Lisbon, Portugal.
- 700 1_
- $a Peris, Ketty $u Institute of Dermatology, Università Cattolica, Rome, Italy; Fondazione Policlinico Universitario A, Gemelli - IRCCS, Rome, Italy.
- 700 1_
- $a Hauschild, Axel $u Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
- 700 1_
- $a Arenberger, Petr $u Department of Dermatovenerology, Third Faculty of Medicine, Charles University of Prague, Prague, Czech Republic.
- 700 1_
- $a Bastholt, Lars $u Department of Oncology, Odense University Hospital, Denmark.
- 700 1_
- $a Bataille, Veronique $u Twin Research and Genetic Epidemiology Unit, School of Basic & Medical Biosciences, King's College London, London, SE1 7EH, UK.
- 700 1_
- $a Del Marmol, Veronique $u Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
- 700 1_
- $a Dréno, Brigitte $u Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France.
- 700 1_
- $a Fargnoli, Maria Concetta $u Department of Dermatology, University of L'Aquila, Italy.
- 700 1_
- $a Grob, Jean-Jacques $u University Department of Dermatology, Marseille, France.
- 700 1_
- $a Höller, Christoph $u Department of Dermatology, Medical University of Vienna, Austria.
- 700 1_
- $a Kaufmann, Roland $u Department of Dermatology, Venerology and Allergology, Frankfurt University Hospital, Frankfurt, Germany.
- 700 1_
- $a Lallas, Aimilios $u First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
- 700 1_
- $a Lebbé, Celeste $u APHP Department of Dermatology, INSERM U976, University Paris 7 Diderot, Saint-Louis University Hospital, Paris, France.
- 700 1_
- $a Malvehy, Josep $u Melanoma Unit, Department of Dermatology, Hospital Clinic, IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Middleton, Mark $u NIHR Biomedical Research Centre, University of Oxford, UK.
- 700 1_
- $a Moreno-Ramirez, David $u Medical-&-Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain.
- 700 1_
- $a Pellacani, Giovanni $u Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy.
- 700 1_
- $a Saiag, Philippe $u University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France.
- 700 1_
- $a Stratigos, Alexander J $u 1st Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece.
- 700 1_
- $a Vieira, Ricardo $u Department of Dermatology and Venereology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.
- 700 1_
- $a Zalaudek, Iris $u Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
- 700 1_
- $a Eggermont, Alexander M M $u Princess Máxima Center, 3584, CS Utrecht, the Netherlands.
- 710 2_
- $a European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 126, č. - (2020), s. 159-177
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31866016 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153740 $b ABA008
- 999 __
- $a ok $b bmc $g 1599372 $s 1115913
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 126 $c - $d 159-177 $e 20191219 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20201125
